Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share price weakness ...

Shares of vaccine makers such as Moderna (MRNA) and Pfizer (PFE) have plunged on news that president-elect Donald Trump has ...

Shares started out the week mixed in Asia after U.S. stocks fell to their worst loss since Election Day. Japan’s Nikkei 225 index dropped 1% to 38,255.65 as the yen regained some strength against the ...

(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Monolithic Power Systems, Inc. MPWR lost 24.68% last week as it was hit by an Edgewater Research analyst report that stated ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

The S&P 500 sank 1.1 per cent and was heading for a losing week and its worst day since October. The Dow Jones Industrial ...

Big pharma stocks needed a shot in the arm after Donald Trump chose vaccine skeptic Robert F. Kennedy Jr. as health secretary ...

U.S. stocks fell to their worst loss since Election Day as the boost that Wall Street got from last week’s victory for Donald ...